TGF-beta Receptor Inhibitors Enhance iPS Cell Reprogramming
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The efficiency and rate of induced pluripotent stem cell (iPS) production are low due to the inefficiency of reprogramming somatic cells, and existing methods rely on continuous expression of exogenous factors, with unknown underlying mechanisms and limited therapeutic applications.
Innovation Solution
Treating somatic cells with a transforming growth factor-beta receptor (TGFβR) inhibitor, such as ALK4, ALK5, or ALK7 inhibitors, to enhance the efficiency and rate of iPS cell production by inhibiting the TGF-β signaling pathway, thereby promoting a pluripotent stem cell phenotype.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If transcription factors are expressed to reprogram somatic cells, then pluripotent cells are generated, but the efficiency and rate of production remain low
Solution Approach 1:
The patent applies parameter changes by modifying the cellular environment through TGF-β signaling pathway inhibition. By changing the signaling parameters (inhibiting TGF-β pathway), the reprogramming efficiency is enhanced, directly addressing the low productivity issue without compromising reliability
Solution Approach 2:
The patent introduces TGF-β pathway inhibitors as intermediary substances that mediate between the transcription factors and the reprogramming process. These inhibitors act as intermediaries to enhance the effect of transcription factors, thereby improving both efficiency and rate of iPS cell production
2Duration of action of stationary object
If exogenous factors are continuously expressed to maintain pluripotent state, then iPS cells are sustained, but the mechanism remains unknown and therapeutic applications are limited
Solution Approach 1:
The patent enables self-service by allowing endogenous factors to replace exogenous factors through TGF-β pathway inhibition. The cells begin to express their own reprogramming factors autonomously, reducing dependency on continuous exogenous factor expression and simplifying the overall system
Solution Approach 2:
The patent applies preliminary action by using TGF-β pathway inhibition to prime the cells for endogenous factor expression. This preliminary intervention facilitates the transition from exogenous to endogenous factor dependency, addressing both the duration and complexity issues
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of TGFβR inhibitors significantly increases the percentage of reprogrammed cells and reduces the time required for iPS cell induction, improving the efficiency and rate of production compared to methods without inhibitor treatment.
Implementation Method 1
contacting the somatic cell or its progeny with an inhibitor of the TGF-β signaling pathway
Data Source
AI summary
In general, iPS cells are produced by delivery of stem cell-associated genes into adult somatic cells (e.g., fibroblasts). Described herein are methods for enhancing the efficiency and rate of induced pluripotent stem cell production by treating somatic cells with a transforming growth factor-beta receptor (TGFβR) inhibitor. Also described herein are iPS cell compositions made according to the methods described herein and iPS cell compositions comprising an iPS cell in an admixture with a TGFβR inhibitor. Further described herein are kits for producing iPS cells using a TGFβR inhibitor.